Axsome Therapeutics (NASDAQ:AXSM) COO Sells $5,726,990.64 in Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM) COO Mark Jacobson sold 35,378 shares of the company’s stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $161.88, for a total transaction of $5,726,990.64. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Axsome Therapeutics Trading Up 0.4%

Shares of NASDAQ:AXSM traded up $0.70 during midday trading on Friday, hitting $163.89. The company had a trading volume of 613,754 shares, compared to its average volume of 697,883. The company has a current ratio of 1.55, a quick ratio of 1.50 and a debt-to-equity ratio of 1.38. Axsome Therapeutics, Inc. has a 12 month low of $86.99 and a 12 month high of $191.50. The firm has a fifty day simple moving average of $175.55 and a 200 day simple moving average of $145.65. The stock has a market cap of $8.38 billion, a price-to-earnings ratio of -44.41, a PEG ratio of 34.93 and a beta of 0.40.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings data on Monday, February 23rd. The company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.14. Axsome Therapeutics had a negative return on equity of 232.61% and a negative net margin of 28.69%.The business had revenue of $196.00 million during the quarter, compared to the consensus estimate of $191.33 million. The company’s quarterly revenue was up 65.0% compared to the same quarter last year. On average, analysts predict that Axsome Therapeutics, Inc. will post -2.79 EPS for the current year.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Oppenheimer reiterated an “outperform” rating and set a $220.00 target price on shares of Axsome Therapeutics in a report on Wednesday, December 31st. Leerink Partners boosted their price objective on Axsome Therapeutics from $150.00 to $205.00 and gave the company an “outperform” rating in a research report on Wednesday, January 28th. Morgan Stanley set a $207.00 target price on shares of Axsome Therapeutics in a report on Tuesday. Cantor Fitzgerald restated an “overweight” rating on shares of Axsome Therapeutics in a report on Wednesday, January 14th. Finally, Mizuho set a $230.00 target price on shares of Axsome Therapeutics in a research note on Thursday, February 19th. Seventeen investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $216.12.

Institutional Investors Weigh In On Axsome Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Versant Capital Management Inc grew its holdings in Axsome Therapeutics by 20,300.0% in the 3rd quarter. Versant Capital Management Inc now owns 204 shares of the company’s stock valued at $25,000 after buying an additional 203 shares in the last quarter. Kemnay Advisory Services Inc. acquired a new stake in Axsome Therapeutics in the 4th quarter worth about $31,000. First Horizon Corp acquired a new stake in Axsome Therapeutics in the 3rd quarter worth about $34,000. Optiver Holding B.V. boosted its holdings in Axsome Therapeutics by 82.3% in the 3rd quarter. Optiver Holding B.V. now owns 288 shares of the company’s stock valued at $35,000 after purchasing an additional 130 shares during the period. Finally, Ameriflex Group Inc. bought a new stake in shares of Axsome Therapeutics in the fourth quarter valued at approximately $37,000. Institutional investors own 81.49% of the company’s stock.

Key Headlines Impacting Axsome Therapeutics

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and a $260 price target and forecasts a large rebound into FY‑2027 (FY‑2027 EPS of $11.87 with strong quarterly ramps). This upbeat long‑term view supports investor optimism. Read More.
• Positive Sentiment: Recent company results showed a Q4 EPS beat and revenue up ~65% year‑over‑year, which provides fundamental support for the stock despite near‑term model revisions. Read More.
• Neutral Sentiment: Reported short interest data in late February shows effectively zero shares short (the published figures contain anomalies/NaN), so short‑position dynamics appear minimal and unlikely to be a near‑term driver. Read More.
• Negative Sentiment: HC Wainwright trimmed multiple near‑term 2026 estimates (Q1‑Q3 and FY‑2026 materially lowered; Q4‑2026 also revised down from prior forecasts). These cuts signal more modest near‑term profitability than previously expected and increase uncertainty for 2026 results. Read More.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.